SpectraScience WavSTAT Optical Biopsy System Featured at Endocsopic Controversies in Gastrointestinal Disease Symposium in Co...
23 Septembre 2013 - 3:00PM
SpectraScience, Inc. (OTCQB:SCIE), a San Diego-based medical device
company, announced that its WavSTAT Optical Biopsy System was
featured at the annual symposium on Endoscopic Controversies in
Gastrointestinal Disease sponsored by the European Society of
Gastrointestinal Endoscopy (ESGE). This year's conference was held
at Copenhagen University Hospital in Copenhagen, Denmark on the
19th and 20th of September.
Dr. Lene Brink performed a live colonoscopy utilizing the
WavSTAT4 Optical Biopsy System to definitively diagnose small and
diminutive polyps and lesions discovered during the demonstration
procedure. Both Denmark and Sweden have established Nurse
Endoscopist programs where specially trained nurses perform many
screening colonoscopies.
"Hospitals with established nurse endoscopist programs are
looking for ways to provide their nurses with a diagnostic
capability equal to or better than that of experienced
gastroenterologists," said Michael Oliver, SpectraScience's Chief
Executive Officer. "Providing the tools to permit expert
diagnosis by nurses makes the entire colorectal cancer screening
system more efficient. Automated assessment tools, like
WavSTAT4 allow the nurses to operate more independently and
efficiently. In addition, the supervising gastroenterologist
is more effective as his minute-to-minute workload is
reduced. This is a real advantage, both clinically and
economically to the hospital, the endoscopists and the
patient."
About the European Society of Gastrointestinal
Endoscopy
The ESGE was officially established in 1964 to promote
endoscopy. The Society has a variety of workshops, grant
programs and education and research committees all focused on the
first and foremost aim of the ESGE: the promotion of good
endoscopy.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that
designs, develops, manufactures and markets light-based analysis
systems capable of determining whether tissue is normal,
pre-cancerous or cancerous without physically removing tissue from
the body. The WavSTAT Optical Biopsy System uses light to optically
diagnose tissue and provide the physician with an immediate
analysis. With approval for sale under the CE Mark for the European
Union, the WavSTAT System is the first commercially available
product that incorporates this innovative technology for clinical
use.
Forward-Looking Statements
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe," "estimate," "project," "expect" or similar expressions.
These statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to,
acceptance of the Company's products and services in the
marketplace, competitive factors, dependence upon third-party
vendors, and other risks detailed in the Company's periodic report
filings with the Securities and Exchange Commission. By making
these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release.
CONTACT: SpectraScience, Inc.
Michael Oliver, Chief Executive Officer
(858) 405-9933
SpectraScience (CE) (USOTC:SCIE)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
SpectraScience (CE) (USOTC:SCIE)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025